Exviera

On 25 September 2024, the European Commission withdrew the marketing authorisation for Exviera (dasabuvir) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, AbbVie Deutschland GmbH & Co. KG, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons. Exviera was granted marketing authorisation in the EU on 15 January 2015 for the treatment of chronic hepatitis C. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2019. The European Public Assessment Report (EPAR) for Exviera is updated to indicate that the marketing authorisation is no longer valid.